demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
Immunostimulants drugs
convalescent plasma treatment CAPSID AlQahtani Li REMAP-CAP ... Rasheed RECOVER Pouladzadeh CP-COVID-19 O’Donnell PlasmAr Sekine ...
immunoglobulin therapy Raman Tabarsi
interferon
IFN beta-1a Kalil ... Darazam ...
IFN beta-1b Darazam ... Rahmani
neutralizing antibody
equine polyclonal antibodies INM005 Lopardo

10 studies excluded by filtering options 0

5275 ILBS-COVID-02 (Bajpai M), 2020 113high risk of bias
5406 Duan, 2020 1134not a RCThigh risk of bias
5446 Sean, 2020 1134not a RCThigh risk of bias
5549 Hegerova, 2020 1134not a RCThigh risk of bias
5761 Joyner, 2020 1313not a RCThigh risk of bias
6159 Gemici, 2020 0130selection pending
6285 Gharebaghi, 2020 110risk of bias not avaialble
6341 PICP19 (Ray), 2020 113high risk of bias
6940 Bihariesingh-Sanchit (SuriCovid), 2021 1310not a RCTrisk of bias not avaialble
9259 Ray, 2022 000selection pending